- Home
- MCVT vs IMNN Comparison
MCVT vs IMNN Comparison
Compare MCVT & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- IMNN
- Stock Information
- Founded
- MCVT 2007
- IMNN 1982
- Country
- MCVT United States
- IMNN United States
- Employees
- MCVT N/A
- IMNN N/A
- Industry
- MCVT Finance Companies
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- MCVT Finance
- IMNN Health Care
- Exchange
- MCVT Nasdaq
- IMNN Nasdaq
- Market Cap
- MCVT 11.1M
- IMNN 12.1M
- IPO Year
- MCVT N/A
- IMNN 1985
- Fundamental
- Price
- MCVT $1.76
- IMNN $0.62
- Analyst Decision
- MCVT
- IMNN Buy
- Analyst Count
- MCVT 0
- IMNN 2
- Target Price
- MCVT N/A
- IMNN $14.00
- AVG Volume (30 Days)
- MCVT 27.6K
- IMNN 3.8M
- Earning Date
- MCVT 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- MCVT N/A
- IMNN N/A
- EPS Growth
- MCVT N/A
- IMNN N/A
- EPS
- MCVT 0.19
- IMNN N/A
- Revenue
- MCVT $3,246,479.00
- IMNN N/A
- Revenue This Year
- MCVT N/A
- IMNN N/A
- Revenue Next Year
- MCVT N/A
- IMNN N/A
- P/E Ratio
- MCVT $9.28
- IMNN N/A
- Revenue Growth
- MCVT N/A
- IMNN N/A
- 52 Week Low
- MCVT $1.13
- IMNN $0.37
- 52 Week High
- MCVT $3.88
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- MCVT 40.38
- IMNN 41.60
- Support Level
- MCVT $1.78
- IMNN $0.48
- Resistance Level
- MCVT $1.85
- IMNN $0.80
- Average True Range (ATR)
- MCVT 0.08
- IMNN 0.08
- MACD
- MCVT -0.02
- IMNN 0.01
- Stochastic Oscillator
- MCVT 4.17
- IMNN 42.24
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).